Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garner

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Communication Disorders|December 31, 2018
The relationship between speech recognition in noise and non-speech recognition in noise test performances: Implications for central auditory processing disorders testingAndrew J Vermiglio, Keerthana Velappan, Paige Heeke, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|September 25, 2014
Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral densityBruce Carr, W Paul Dmowski, Chris O'Brien, et al.
Journal of Clinical Medicine|December 24, 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of AdministrationJacques Donnez, Olivier Donnez, Jean Tourniaire, et al.
Molecular Cell|December 24, 2014
Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenanceJian Ouyang, Elizabeth Garner, Alexander Hallet, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|July 26, 2013
Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled studyMichael P Diamond, Bruce Carr, W Paul Dmowski, et al.
Lancet (London, England)|September 18, 2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trialsJacques Donnez, Hugh S Taylor, Elizabeth A Stewart, et al.
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Journal of Epidemiology and Community Health|August 16, 2005
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectivesNancy Krieger, Ilana Löwy, Robert Aronowitz, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Nature Methods|May 2, 2017
Mapping the genomic landscape of CRISPR-Cas9 cleavagePeter Cameron, Chris K Fuller, Paul D Donohoue, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Communication Disorders|December 31, 2018
The relationship between speech recognition in noise and non-speech recognition in noise test performances: Implications for central auditory processing disorders testingAndrew J Vermiglio, Keerthana Velappan, Paige Heeke, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|September 25, 2014
Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral densityBruce Carr, W Paul Dmowski, Chris O'Brien, et al.
Journal of Clinical Medicine|December 24, 2021
Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of AdministrationJacques Donnez, Olivier Donnez, Jean Tourniaire, et al.
Molecular Cell|December 24, 2014
Noncovalent interactions with SUMO and ubiquitin orchestrate distinct functions of the SLX4 complex in genome maintenanceJian Ouyang, Elizabeth Garner, Alexander Hallet, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|July 26, 2013
Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled studyMichael P Diamond, Bruce Carr, W Paul Dmowski, et al.
Lancet (London, England)|September 18, 2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trialsJacques Donnez, Hugh S Taylor, Elizabeth A Stewart, et al.
Vaccine|July 9, 2013
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in malesStephen E Goldstone, Heiko Jessen, Joel M Palefsky, et al.
Journal of Epidemiology and Community Health|August 16, 2005
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectivesNancy Krieger, Ilana Löwy, Robert Aronowitz, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Nature Methods|May 2, 2017
Mapping the genomic landscape of CRISPR-Cas9 cleavagePeter Cameron, Chris K Fuller, Paul D Donohoue, et al.
Pageof 3